



Division Directive Number
4.101
Effective Date: 04.11.07
Reviewed: 10.08.08; 03.05.10;
11.01.11

Bernard Simons
Bernard Simons, Director

Title: Quarterly Drug Review Components

Applies to: Division of Developmental Disabilities Habilitation Center Campuses

Purpose: To establish the core components for the Quarterly Drug Review, which is to be completed for all consumers served in state operated Habilitation Centers.

A quarterly review of a consumer's drug regimen is required by the ICF/MR regulations and is to be documented in the clinical record by the physician.

- A. Effective immediately all quarterly drug reviews will include no less than the following information:
1. Drug prescribed
 2. Dosage
 3. Indication for use
 4. Target symptoms
 5. Changes in dosage this quarter
 6. Supporting lab data if indicated
 7. Is drug managing the illness/condition?
 8. Side effects noted
 9. New drugs prescribed this quarter, with the above mentioned information supplied
 10. If psychoactive drugs are prescribed for the consumer, the following considerations will also be addressed:
 - a. Review of effectiveness of medication, including mental status exam findings pertinent behavioral events and changes in the target behaviors/symptoms, concluding with recommended changes.
 - b. Review of effectiveness of Behavioral Support Plans. This will include pertinent behavioral events and changes in target behaviors not discussed above and conclude with recommended changes.
 - c. Review of side effects including recent laboratory test, Tardive Dyskinesia evaluation, MOSES side effect survey, and other medical sequeli such as metabolic syndrome.
 - d. Rational/justification for any ongoing polypharmacy of drugs in the same therapeutic classification.
 - e. Current contingent medication reduction plan or justification for no reductions.
 - f. Other recommendations.
- B. The consumer's attending physician will document in the clinical record his/her review and validation of the information collected and resulting conclusions. The physician will also document any changes made to the consumer's drug regimen as the result of the quarterly review, the associated rationale, and any plans for monitoring and follow-up.